Eli Lilly and Company $LLY Shares Bought by Jackson Square Capital LLC

Key Points

• Jackson Square Capital LLC increased its holdings in Eli Lilly and Company by 6.0%, making it the firm's 5th largest position with a total value of approximately $15.83 million.
• Several analysts have adjusted their ratings and target prices for Eli Lilly, with Leerink Partners downgrading the stock from "strong-buy" to "hold" while DZ Bank upgraded it to a "strong-buy".
• Eli Lilly reported earnings per share of $6.31 for the last quarter, significantly exceeding analysts' estimates and showing a 37.6% year-over-year revenue increase.

Jackson Square Capital LLC lifted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,311 shares of the company's stock after buying an additional 1,149 shares during the quarter. Eli Lilly and Company comprises 3.5% of Jackson Square Capital LLC's portfolio, making the stock its 5th biggest holding. Jackson Square Capital LLC's holdings in Eli Lilly and Company were worth $15,833,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Sarasin & Partners LLP boosted its holdings in shares of Eli Lilly and Company by 4.3% in the 2nd quarter. Sarasin & Partners LLP now owns 237,793 shares of the company's stock worth $185,367,000 after purchasing an additional 9,735 shares during the period. Gilman Hill Asset Management LLC grew its stake in Eli Lilly and Company by 1.4% during the 2nd quarter. Gilman Hill Asset Management LLC now owns 1,636 shares of the company's stock worth $1,275,000 after buying an additional 22 shares during the last quarter. Lineweaver Wealth Advisors LLC grew its stake in Eli Lilly and Company by 18.7% during the 2nd quarter. Lineweaver Wealth Advisors LLC now owns 2,752 shares of the company's stock valued at $2,146,000 after purchasing an additional 433 shares during the last quarter. Channel Wealth LLC boosted its stake in shares of Eli Lilly and Company by 2.7% in the second quarter. Channel Wealth LLC now owns 10,217 shares of the company's stock worth $7,965,000 after buying an additional 270 shares during the last quarter. Finally, Pines Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 7.1% in the second quarter. Pines Wealth Management LLC now owns 4,370 shares of the company's stock worth $3,412,000 after buying an additional 291 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 1.2%

NYSE:LLY traded down $9.41 on Friday, reaching $753.52. The stock had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $939.86. The company has a 50-day moving average of $738.37 and a 200 day moving average of $771.89. The stock has a market cap of $713.18 billion, a P/E ratio of 49.25, a price-to-earnings-growth ratio of 1.06 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the company posted $3.92 earnings per share. The company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company's payout ratio is 39.22%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on LLY. Berenberg Bank reissued a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Finally, DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.